Biologic aging, frailty, and age-related disease in chronic HIV infection

Current Opinion in HIV and AIDS

Volumn 9, Issue 4, 2014, Pages 412-418

  Brothers, Thomas D ^a   Rockwood, Kenneth ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

aging; frailty; health status; HIV; older adults

Indexed keywords

AGED; AGING; CD4 LYMPHOCYTE COUNT; CELL AGING; CELL COMMUNICATION; DNA DAMAGE; FRAIL ELDERLY; GENE EXPRESSION; GENE MUTATION; GROWTH DISORDER; HEALTH STATUS; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MIXED INFECTION; NEOPLASM; ORGANELLE SHAPE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; SYNDROME; TELOMERE SHORTENING; TISSUE INJURY; CHRONIC DISEASE; COMORBIDITY; HIV INFECTIONS; PREVALENCE;

AGING; CHRONIC DISEASE; COMORBIDITY; HIV INFECTIONS; HUMANS; PREVALENCE;

EID: 84902283746     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000070     Document Type: Review

References (76)

1. Sabin CA. Do people with HIV infection have a normal life expectancy in the era of combination antiretroviral therapy? BMC Med 2013; 11:251.
2. Guaraldi G, Cossarizza A, Franceschi C, et al. Life expectancy in the immune recovery era: the evolving scenario of the HIV epidemic in northern Italy. J Acquir Immune Defic Syndr 2014; 65:175-181.
3. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet 2013; 382:1525-1533.
4. Pathai S, Bajillan H, Landay AL, High KP. Is HIV a model of accelerated or accentuated aging? J Gerontol A Biol Sci Med Sci 2013; doi: 10. 1093/ gerona/glt168. [Epub ahead of print]
5. Gompertz B. On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies. Philos Trans R Soc Lond 1825; 115:513-583.
6. Strulik H, Vollmer S. Long-run trends of human aging and longevity. J Popul Econ 2013; 26:1303-1323.
7. Ló pez-Otn C, Blasco MA, Partridge L, et al. The hallmarks of aging. Cell 2013; 153:1194-1217.
8. Moskalev AA, Shaposhnikov MV, Plyusnina EN, et al. The role of DNA damage and repair in aging through the prism of Koch-like criteria. Ageing Res Rev 2013; 12:661-684.
9. Armanios M. Telomeres and age-related disease: how telomere biology informs clinical paradigms. J Clin Invest 2013; 123:996-1002.
10. Powers ET, Morimoto RI, Dillin A, et al. Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem 2009; 78:959-991.
11. Talens RP, Christensen K, Putter H, et al. Epigenetic variation during the adult lifespan: cross-sectional and longitudinal data on monozygotic twin pairs. Aging Cell 2012; 11:694-703.
12. Green DR, Galluzzi L, Kroemer G. Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science 2011; 333:1109-1112.
13. Salminen A, Kaarniranta K, Kauppinen A. Inflammaging: disturbed interplay between autophagy and inflammasomes. Aging (Albany NY) 2012; 4:166-L 175.
14. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011; 62:141-155.
15. Armah KA, McGinnis K, Baker J, et al. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis 2012; 55:126-136.
16. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
17. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4 count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
18. Hearps AC, Martin GE, Rajasuriar R, Crowe SM. Inflammatory co-morbidities in HIV individuals: learning lessons from healthy ageing. Curr HIV/AIDS Rep 2014; 11:20-34.
19. Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity 2013; 39:633-645.
20. Plaeger SF, Collins BS, Musib R, et al. Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary. AIDS Res Hum Retroviruses 2012; 28:469-477.
21. Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. Lancet 2013; 381:752-762.
22. Howlett SE, Rockwood K. New horizons in frailty: ageing and the deficitscaling problem. Age Ageing 2013; 42:416-423.
23. Song X, Mitnitski A, Rockwood K. Nontraditional risk factors combine to predict Alzheimer disease and dementia. Neurology 2011; 77:227-234.
24. Wallace LMK, Theou O, Kirkland SA, et al. Accumulation of nontraditional risk factors for coronary heart disease is associated with incident coronary heart disease hospitalization and death. PLoS One 2014; 9:e90475.
25. Moorhouse P, Rockwood K. Frailty and its quantitative clinical evaluation. J R Coll Physicians Edinb 2011; 42:333-340.
26. Kirkwood TB. Understanding the odd science of aging. Cell 2005; 120:437-447.
27. Kirkwood TBL. Systems biology of ageing and longevity. Philos Trans R Soc Lond B Biol Sci 2011; 366:64-70.
28. Mitnitski A, Song X, Rockwood K. Assessing biological aging: the origin of deficit accumulation. Biogerontology 2013; 14:709-717.
29. Rockwood K, Mitnitski A. Frailty defined by deficit accumulation and geriatric medicine defined by frailty. Clin Geriatr Med 2011; 27:17-26.
30. Steinsaltz D, Mohan G, Kolb M. Markov models of aging: theory and practice. Exp Gerontol 2012; 47:792-802.
31. Tchkonia T, Zhu Y, van Deursen J, et al. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest 2013; 123:966-972.
32. Ohtani N, Hara E. Roles and mechanisms of cellular senescence in regulation of tissue homeostasis. Cancer Sci 2013; 104:525-530.
33. Blagosklonny MV. Prospective treatment of age-related diseases by slowing down aging. Am J Pathol 2012; 181:1142-1146.
34. Blagosklonny MV. Hormesis does not make sense except in the light of TOR-driven aging. Aging (Albany NY) 2011; 3:1051-1062.
35. Hubbard RE, Searle SD, Mitnitski A, Rockwood K. Effect of smoking on the accumulation of deficits, frailty and survival in older adults: a secondary analysis from the Canadian Study of Health and Aging. J Nutr Health Aging 2009; 13:468-472.
36. Wang C, Song X, Mitnitski A, et al. Gender differences in the relationship between smoking and frailty: results from the Beijing Longitudinal Study of Aging. J Gerontol A Biol Sci Med Sci 2013; 68:338-346.
37. Brothers TD, Theou O, Rockwood K. Frailty and migration in middle-aged and older Europeans. Arch Gerontol Geriatr 2014; 58:63-68.
38. Armah KA, Quinn EK, Cheng DM, et al. Human immunodeficiency virus, hepatitis C, and inflammatory biomarkers in individuals with alcohol problems: a cross-sectional study. BMC Infect Dis 2013; 13:399.
39. Pé rez-Matute P, Pé rez-Martínez L, Blanco JR, Oteo JA. Role of mitochondria in HIV infection and associated metabolic disorders: focus on nonalcoholic fatty liver disease and lipodystrophy syndrome. Oxid Med Cell Longev 2013; 2013:493413.
40. Koch S, Solana R, Dela Rosa O, Pawelec G. Human cytomegalovirus infection and T cell immunosenescence: a mini review. Mech Aging Dev 2006; 127:538-543.
41. Naeger DM, Martin JN, Sinclair E, et al. Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One 2010; 5:e8886.
42. Hunt PW, Martin JN, Sinclair E, et al. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4 T cell recovery on antiretroviral therapy. J Infect Dis 2011; 203:1474-1483.
43. Theou O, Brothers TD, Penã FG, Mitnitski A, Rockwood K. Identifying common characteristics of frailty across seven scales. J Am Geriatr Soc 2014; doi: 10. 1111/jgs. 12773. [Epub ahead of print]
44. Walston J. Frailty: the search for underlying causes. Sci Aging Knowledge Environ 2004; 2004:e4.
45. Fried L, Tangen C, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56:M146-M156.
46. Mitnitski AB, Mogilner AJ, Rockwood K. Accumulation of deficits as a proxy measure of aging. ScientificWorldJournal 2001; 1:323-336.
47. Searle SD, Mitnitski A, Gahbauer EA, et al. A standard procedure for creating a frailty index. BMC Geriatr 2008; 8:24.
48. Pena F, Theou O, Wallace L, et al. Comparison of alternate scoring of variables on the performance of the frailty index. BMC Geriatr 2014; 14:25.
49. Theou O, Brothers TD, Mitnitski A, Rockwood K. Operationalization of frailty using eight scales and comparison of their ability to predict all-cause mortality. J Am Geriatr Soc 2013; 61:1537-1551.
50. Sourial N, Bergman H, Karunananthan S, et al. Contribution of frailty markers in explaining differences among individuals in five samples of older persons. J Gerontol A Biol Sci Med Sci 2012; 67:1197-1204.
51. Sternberg SA, Schwartz AW, Karunananthan S, et al. The identification of frailty: a systematic literature review. J Am Geriatr Soc 2011; 59:2129-2138.
52. Rothman MD, Leo-Summers L, Gill TM. Prognostic significance of potential frailty criteria. J Am Geriatr Soc 2008; 56:2211-2216.
53. Drubbel I, de Wit NJ, Bleijenberg N, et al. Prediction of adverse health outcomes in older people using a frailty index based on routine primary care data. J Gerontol A Biol Sci Med Sci 2013; 68:301-308.
54. Evans SJ, Sayers M, Mitnitski A, Rockwood K. The risk of adverse outcomes in hospitalized older patients in relation to a frailty index based on a comprehensive geriatric assessment. Age Ageing 2014; 43:127-132.
55. Krishnan M, Beck S, Havelock W, et al. Predicting outcome after hip fracture: using a frailty index to integrate comprehensive geriatric assessment results. Age Ageing 2014; 43:122-126.
56. Singh I, Gallacher J, Davis K, et al. Predictors of adverse outcomes on an acute geriatric rehabilitation ward. Age Ageing 2012; 41:242-246.
57. Jones D, Song X, Mitnitski A, Rockwood K. Evaluation of a frailty index based on a comprehensive geriatric assessment in a population based study of elderly Canadians. Aging Clin Exp Res 2005; 17:465-471.
58. Brothers TD, Kirkland S, Guaraldi G, et al. Frailty in people aging with human immunodeficiency virus (HIV) infection. J Infect Dis 2014 [In press].
59. Womack JA, Goulet JL, Gibert C, et al. Physiologic frailty and fragility fracture in HIV-infected male veterans. Clin Infect Dis 2013; 56:1498-1504.
60. Erlandson KM, Allshouse AA, Jankowski CM, et al. Risk factors for falls in HIVinfected persons. J Acquir Immune Defic Syndr 2012; 61:484-489.
61. Onen NF, Agbebi A, Shacham E, et al. Frailty among HIV-infected persons in an urban outpatient care setting. J Infect 2009; 59:346-352.
62. Piggott DA, Muzaale AD, Mehta SH, et al. Frailty, HIV infection, and mortality in an aging cohort of injection drug users. PLoS One 2013; 8:e54910.
63. Althoff KN, Jacobson LP, Cranston RD, et al. Age, comorbidities, and AIDS predict a frailty phenotype in men who have sex with men. J Gerontol A Biol Sci Med Sci 2014; 69:189-198.
64. Erlandson KM, Allshouse AA, Jankowski CM, et al. Comparison of functional status instruments in HIV-infected adults on effective antiretroviral therapy. HIV Clin Trials 2012; 13:324-334.
65. Ianas V, Berg E, Mohler MJ, et al. Antiretroviral therapy protects against frailty in HIV-1 infection. J Int Assoc Provid AIDS Care 2012; 12:62-66.
66. Justice AC, Freiberg MS, Tracy R, et al. Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis 2012; 54:984-994.
67. Terzian AS, Holman S, Nathwani N, et al. Factors associated with preclinical disability and frailty among HIV-infected and HIV-uninfected women in the era of cART. J Womens Health (Larchmt) 2009; 18:1965-1974.
68. Pathai S, Gilbert C, Weiss HA, et al. Frailty in HIV-infected adults in South Africa. J Acquir Immune Defic Syndr 2012; 62:43-51.
69. Adeyemi O, Livak B. Higher Veterans Aging Cohort Study (VACS) index scores in HIV-positive adults with CD4 counts < 200 cells/mm3 despite viral suppression. J Acquir Immune Defic Syndr 2013; 63:e78-e81.
70. Desquilbet L, Jacobson LP, Fried LP, et al. A frailty-related phenotype before HAART initiation as an independent risk factor for AIDS or death after HAART among HIV-infected men. J Gerontol A Biol Sci Med Sci 2011; 66:1030-1038.
71. Oursler K, Tate J, Gill TM, et al. Association of the VACS index with exercise capacity in HIV-infected adults. AIDS Res Hum Retroviruses 2013; 29:1218-1223.
72. Marquine MJ, Umlauf A, Rooney AS, et al. The Veterans Aging Cohort Study index is associated with concurrent risk for neurocognitive impairment. J Acquir Immune Defic Syndr 2014; 65:190-197.
73. Justice AC, Tate JP, Freiberg MS, et al. Reply to Chow et al. Clin Infect Dis 2012; 55:751-752.
74. Tate JP, Justice AC, Hughes MD, et al. An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS 2013; 27:563-572.
75. Mitnitski A, Song X, Rockwood K. Trajectories of changes over twelve years in the health status of Canadians from late middle age. Exp Gerontol 2012; 47:893-899.
76. Andrew MK, Mitnitski AB, Rockwood K. Social vulnerability, frailty and mortality in elderly people. PLoS One 2008; 3:e2232.